Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HB2198 SAD Study in Healthy Participants
NCT07439263Phase 1Recruiting
- Sponsor
- Hinge Bio, Inc.
- Start
- Mar 2026
- Primary completion
- Aug 2026
- Modality
- Antibody Conjugates, Trispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing HB2198 with Placebo (2 arms). Primary endpoints: Safety and Tolerability at Month 2 and Dose Limiting Toxicities at Day 28. Started Mar 2026; status: recruiting.
02
Drugs
HB2198
Beyond the preview
Go deeper on NCT07439263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07439263.